Insider Selling: Apria, Inc. (NYSE:APR) EVP Sells 2,458 Shares of Stock

Apria, Inc. (NYSE:APR) EVP Mark E. Litkovitz sold 2,458 shares of the stock in a transaction that occurred on Friday, September 10th. The stock was sold at an average price of $37.66, for a total value of $92,568.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Apria stock opened at $37.98 on Friday. The company has a debt-to-equity ratio of 215.95, a current ratio of 1.21 and a quick ratio of 1.18. The company has a market capitalization of $1.34 billion and a PE ratio of 0.82. Apria, Inc. has a one year low of $20.07 and a one year high of $38.47. The business has a 50 day simple moving average of $32.73 and a 200 day simple moving average of $29.47.

Apria (NYSE:APR) last announced its earnings results on Thursday, August 5th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. Equities analysts anticipate that Apria, Inc. will post 1.63 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. American International Group Inc. bought a new stake in Apria during the 1st quarter worth approximately $123,000. BlackRock Inc. bought a new stake in Apria during the 1st quarter worth approximately $10,898,000. New York State Common Retirement Fund bought a new stake in Apria during the 1st quarter worth approximately $95,000. UBS Group AG bought a new stake in Apria during the 1st quarter worth approximately $78,000. Finally, JPMorgan Chase & Co. acquired a new position in Apria during the 1st quarter worth about $79,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

APR has been the topic of several research analyst reports. Citigroup raised their price objective on shares of Apria from $33.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, August 6th. Piper Sandler boosted their price objective on shares of Apria from $33.00 to $35.00 and gave the stock an “overweight” rating in a report on Friday, August 6th. The Goldman Sachs Group cut Apria from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $32.00 to $29.00 in a research report on Monday, July 19th. started coverage on Apria in a research report on Wednesday, June 30th. They set a “buy” rating and a $33.00 price objective on the stock. Finally, Zacks Investment Research upgraded shares of Apria from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research report on Tuesday, August 10th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $31.86.

Apria Company Profile

Apria, Inc provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products.

Recommended Story: Growth Stocks

Receive News & Ratings for Apria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apria and related companies with MarketBeat.com's FREE daily email newsletter.